Category: Neuroscience

New Biology-Driven Drug Discoveries Needed for Treating of Alzheimer’s

Alzheimer’s disease (AD) is a slowly progressing neurodegenerative disorder that affects millions of people worldwide, leaving behind an immense psychological, emotional, and financial burden on patients, caregivers, and healthcare systems. There are no existing therapies to prevent the onset or...

/ June 17, 2019

Q&A with Dr. Gregory Carter: Developing Computational Strategies and the MODEL-AD Consortium

Gregory Carter, Ph.D., is an Associate Professor at The Jackson Laboratory. His work is focused on developing computational strategies using genetic data to understand complex genetic systems. We recently spoke with Dr. Carter about his research and the MODEL-AD consortium....

Meta-analysis of AMP-AD Datasets Defines the Transcriptional Landscape of Alzheimer’s Disease

The Accelerating Medicines Partnership - Alzheimer’s Disease (AMP-AD) Consortium was formed to accelerate the development of diagnostics and therapeutics for this devastating and complex disease. One roadblock to development is the lack of good pre-clinical models, as efficacy in clinical...

/ January 31, 2019

Q&A with Dr. Stefan Prokop – Alzheimer’s: From the Amyloid Hypothesis to the Cellular Phase and Beyond

Stefan Prokop, MD, is a Neuropathologist and Research Fellow at the University of Pennsylvania School of Medicine. His work is focused on Alzheimer’s Disease (AD) with a specific interest in the role of the immune system in AD pathogenesis and...

Researcher Profiles: How NanoString® Neuroscience Grant Program Winners are Utilizing nCounter® Technology

Earlier this year, five neuro grant program applicants were awarded nCounter® Neuropathology or Neuroinflammation Panels to profile 24 samples. Applications spanned a wide range of disease specific applications with the winning projects focused on Alzheimer’s Disease (AD), Parkinson’s Disease (PD),...